Log in

NASDAQ:XOMAXOMA Stock Price, Forecast & News

$21.75
+0.18 (+0.83 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.79
Now: $21.75
$21.81
50-Day Range
$19.30
MA: $22.51
$25.51
52-Week Range
$14.03
Now: $21.75
$28.85
Volume29,564 shs
Average Volume40,898 shs
Market Capitalization$239.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More
XOMA logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.37 million
Book Value$5.03 per share

Profitability

Net Income$-1,980,000.00
Net Margins-102.32%

Miscellaneous

Employees11
Market Cap$239.69 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA (NASDAQ:XOMA) Frequently Asked Questions

How has XOMA's stock been impacted by COVID-19 (Coronavirus)?

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 11.5% and is now trading at $21.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.33. The biotechnology company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $3.40 million. XOMA had a negative return on equity of 34.27% and a negative net margin of 102.32%. View XOMA's earnings history.

What price target have analysts set for XOMA?

2 brokers have issued twelve-month price targets for XOMA's stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate XOMA's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 35.6% from the stock's current price. View analysts' price targets for XOMA.

Has XOMA been receiving favorable news coverage?

News headlines about XOMA stock have trended neutral on Saturday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XOMA earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutXOMA.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by a number of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (1.89%), BlackRock Inc. (1.78%), Geode Capital Management LLC (0.54%), Cadence Capital Management LLC (0.50%), EAM Investors LLC (0.36%) and Invesco Ltd. (0.29%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View institutional ownership trends for XOMA.

Which major investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Two Sigma Investments LP, Geode Capital Management LLC, BlackRock Inc., Alps Advisors Inc., First Manhattan Co., and EAM Investors LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns. View insider buying and selling activity for XOMA.

Which major investors are buying XOMA stock?

XOMA stock was bought by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Invesco Ltd., Stonepine Capital Management LLC, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, and Value Fund L P Biotechnology. View insider buying and selling activity for XOMA.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $21.75.

How big of a company is XOMA?

XOMA has a market capitalization of $239.69 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.